276 related articles for article (PubMed ID: 37370391)
1. Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.
Kontou A; Kourti M; Iosifidis E; Sarafidis K; Roilides E
Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370391
[TBL] [Abstract][Full Text] [Related]
2. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
7. Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Venuti F; Romani L; De Luca M; Tripiciano C; Palma P; Chiriaco M; Finocchi A; Lancella L
Microorganisms; 2023 Jul; 11(7):. PubMed ID: 37512970
[TBL] [Abstract][Full Text] [Related]
8. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
9. [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].
Mischnik A; Lübbert C; Mutters NT
Internist (Berl); 2018 Dec; 59(12):1335-1343. PubMed ID: 30264191
[TBL] [Abstract][Full Text] [Related]
10. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
12. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
15. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
Wright H; Bonomo RA; Paterson DL
Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
17. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
19. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]